Merck KGaA (MRK) Given Consensus Rating of “Buy” by Analysts

Shares of Merck KGaA (FRA:MRK) have been given an average rating of “Buy” by the twenty-two analysts that are presently covering the stock, MarketBeat reports. Eleven research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is €107.42 ($132.62).

MRK has been the subject of several research analyst reports. Oddo Bhf set a €125.00 ($154.32) price objective on shares of Merck KGaA and gave the company a “buy” rating in a research report on Friday, October 27th. Kepler Capital Markets set a €115.00 ($141.98) price objective on shares of Merck KGaA and gave the company a “buy” rating in a research report on Monday, November 6th. equinet set a €112.00 ($138.27) price objective on shares of Merck KGaA and gave the company a “buy” rating in a research report on Friday, November 3rd. Berenberg Bank set a €116.00 ($143.21) price objective on shares of Merck KGaA and gave the company a “buy” rating in a research report on Thursday, November 9th. Finally, Warburg Research set a €115.00 ($141.98) price objective on shares of Merck KGaA and gave the company a “buy” rating in a research report on Thursday, November 9th.

Shares of Merck KGaA (MRK) opened at €81.96 ($101.19) on Tuesday. Merck KGaA has a fifty-two week low of €80.50 ($99.38) and a fifty-two week high of €115.00 ($141.98). The stock has a market cap of $10,480.00 and a PE ratio of 19.19.

ILLEGAL ACTIVITY WARNING: “Merck KGaA (MRK) Given Consensus Rating of “Buy” by Analysts” was first reported by American Banking News and is the sole property of of American Banking News. If you are reading this story on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The correct version of this story can be viewed at https://www.americanbankingnews.com/2018/02/13/merck-kgaa-mrk-given-consensus-rating-of-buy-by-analysts.html.

About Merck KGaA

MERCK Kommanditgesellschaft auf Aktien provides products in the healthcare, life science, and performance materials sectors worldwide. The company offers prescription medicines to treat colorectal cancer, head and neck tumors, multiple sclerosis, infertility, growth hormone disorders, cardiovascular disorders, diabetes, and thyroid disorders; diagnostics and prescription drugs for allergen immunotherapy; and biosimilars for oncology and inflammatory disorders.

Analyst Recommendations for Merck KGaA (FRA:MRK)

Receive News & Ratings for Merck KGaA Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck KGaA and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply